Combined with the integrated Ion Torrent Genexus sequencer, the new assays provide valuable genomic information in the field of aneuploidy analysis.
To expand the benefits of genomic testing research for reproductive health laboratories, US company Thermo Fisher Scientific has launched two new options based on next-generation sequencing to support preimplantation genetic testing-aneuploidy (PGT-A) that is being commonly used to inform in vitro research on in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI).
The Ion ReproSeq PGT-A Kit and Ion AmpliSeq Polyploidy Kit mark the first investigational-use reproductive health assays available on the Ion Torrent Genexus integrated sequencer, offering comprehensive sample-to-result workflows for aneuploidy analysis .
In all regions of the world, approximately 17.5% of the adult population experiences infertility. Subsequently, the use of assisted reproductive technology (ART), such as IVF procedures, is growing and has more than doubled in the last decade. The PGT-A test identifies chromosomal abnormalities in embryo samples and has become commonplace in IVF and ICSI research to advance future fertility care options.
With the ReproSeq PGT-A Kit now available on the Genexus Integrated Sequencer, more laboratories will have the ability to explore comprehensive PGT-A assays. With the ReproSeq PGT-A Kit, researchers can study vital scientific and genetic insights that can increase the likelihood of successful future pregnancies and improve the health of future generations.
